Communication Dans Un Congrès Année : 2025

Lu-PSMA-Dose, a French retrospective multicentric dosimetry study of 177 Lu-PSMA treatments for metastatic castration-resistant prostate cancer

Didier Franck
  • Fonction : Auteur
  • PersonId : 1073260

Résumé

The main objective of the Lu-PSMA-Dose study, sponsored by ASNR, is to estimate retrospectively the individual absorbed dose delivered to patients treated with 177Lu-PSMA for metastatic castration-resistant prostate cancer (mCRPC). Secondary objectives are: to develop a dose estimation method easily applicable in clinical practice, to provide knowledge on 177Lu-PSMA treatments by computing absorbed doses to lesions and organs at risk on a representative cohort of patients, to determine associated dose uncertainties using a Bayesian network, to carry out an ancillary study on toxicities and to compare them with calculated absorbed doses.

Fichier principal
Vignette du fichier
Lamart_Lu-PSMA-Dose_AAPM_v5.pdf (93.24 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-05480554 , version 1 (27-01-2026)

Licence

Identifiants

  • HAL Id : hal-05480554 , version 1

Citer

Stéphanie Lamart, Alexandre Pignard, Jean-Noel Badel, T Baudier, David Broggio, et al.. Lu-PSMA-Dose, a French retrospective multicentric dosimetry study of 177 Lu-PSMA treatments for metastatic castration-resistant prostate cancer. AAPM 67th Annual Meeting & Exhibition 2025, American Association of Physicists in Medicine (AAPM), Jul 2025, Washignton DC, United States. ⟨hal-05480554⟩
1504 Consultations
113 Téléchargements

Partager

  • More